MBTPS1 and myeloid sarcoma: The cross-talk between adenosine signaling and S1P may be clinically relevant because receptors for S1P are targeted by fingolimod, a widely used drug for MS, and whose direct action on the CNS remains unclear (Soliven et al., 2011).